Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 19/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 19/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medorinone SCHEMBL121782 | 0.77 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL10729972 | 0.77 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL10377596 | 0.77 | PDE3B (0.62) | PDE3BPDE3A | |
| SCHEMBL10378903 | 0.76 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL10731400 | 0.73 | PDE3B (0.59) | PDE3BPDE3A | |
| SCHEMBL10726017 | 0.73 | PDE3B (0.75) | PDE3BPDE3A | |
| SCHEMBL7378876 | 0.73 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL14090714 | 0.73 | PDE3B (0.62) | PDE3BPDE3A | |
| SCHEMBL10810836 | 0.73 | PDE3B (0.71) | PDE3BPDE3A | |
| SCHEMBL10725028 | 0.73 | PDE3B (0.57) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115244050-B | Novel HPK1 inhibitor and preparation method and application thereof | 轶诺(浙江)药业有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115244050-A | Novel HPK1 inhibitor and preparation method and application thereof | 轶诺(浙江)药业有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-114340740-A | Beta adrenergic agonists and methods of use thereof | 库拉森疗法公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-113336747-A | Novel HPK1 inhibitor and preparation method and application thereof | 轶诺(浙江)药业有限公司 | 2021-09-03 | — | — | CN | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-4716170-A | 5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-1,6-naphthyridin-2(1H)-ones and their cardiotonic use | STERLING DRUG INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4697021-A | 1,6-dihydro-6-oxo-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-09-29 | — | — | US | disclosed |
| US-4657915-A | INOTROPIC AGENTS | STERLING DRUG INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4634772-A | 2-[2-(di-lower-alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0189853-A2 | 1,6-Naphthyridin-2(1H)-ones having cardiotonic activity and preparation | STERLING DRUG INC. (US) | 1986-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | PDE3B 253/4885PDE3A 210/4885TP53 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.